Brief: Sanofi To Acquire Blueprint Medicines

Blueprint Medicines

02/06/2025 06:04

June 2 (Reuters) - Sanofi SASY.PA:

PRESS RELEASE: SANOFI TO ACQUIRE BLUEPRINT MEDICINES, EXPANDING PORTFOLIO IN RARE IMMUNOLOGICAL DISEASE AND ADDING EARLY-STAGE PIPELINE IN IMMUNOLOGY

SANOFI TO FINANCE DEAL WITH CASH AND NEW DEBT

SANOFI EXPECTS TO COMPLETE ACQUISITION IN Q3 2025

WILL PAY $129.00 PER SHARE IN CASH AT CLOSING, REPRESENTING AN EQUITY VALUE OF APPROXIMATELY $9.1 BILLION FOR BLUEPRINT

ACQUISITION IMMEDIATELY ACCRETIVE TO GROSS MARGIN

BLUEPRINT SHAREHOLDERS WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) WHICH WILL ENTITLE HOLDER TO RECEIVE TWO POTENTIAL MILESTONE PAYMENTS OF $2 AND $4 PER CVR FOR ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY MILESTONES FOR BLU-808

TOTAL EQUITY VALUE OF BLUEPRINT TRANSACTION, INCLUDING POTENTIAL CVR PAYMENTS, REPRESENTS APPROXIMATELY $9.5 BILLION ON A FULLY DILUTED BASIS

Source text: nGNE52PHt7

Further company coverage: SASY.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))